On October 7, 2026, Stockholm-based Natural Cycles announced an expanded investment in Canada. The company says its Canadian user base has grown threefold since Health Canada authorized the app as a Class II medical device in 2024. Natural Cycles calls it the only digital contraceptive app authorized by Health Canada. The expansion has three parts: Canada-specific clinical research, medical education, and consumer awareness. New product launches for Canadian users are promised before the end of 2026.

Why It Matters

Digital contraception now has three moving parts: regulator-cleared algorithms, wearable temperature data from Oura, Apple Watch and Natural Cycles' own band, and a consumer shift away from hormones. Canada suits that model. It has a single national device regulator, a Class II authorization already granted, and a reported contraceptive gap that is large. A threefold rise in users without paid mass marketing supports the company's "organic demand" claim, and hiring a well-known Canadian consumer marketer suggests paid growth will follow. The scrutiny will grow with it. The 8,798-user analysis is still a preprint. On September 30 *The BMJ* published an analysis arguing that menstrual-tracking and "cycle syncing" apps lack evidence of benefit and carry privacy risks, and French researchers at INSERM have previously warned about relying on fertility apps for contraception. Expect clinicians to focus on the gap between 98% perfect use and 93% typical use. Natural Cycles' plan to put OB-GYNs on an advisory board and present at SOGC looks designed to get ahead of that.

The evidence package is central. Natural Cycles cites an analysis of 8,798 Canadian users covering more than 7,000 woman-years of real-world use, which it says showed effectiveness consistent with its global data. The analysis is a preprint on medRxiv and hasn't been peer reviewed. It was presented at the Society of Obstetricians and Gynaecologists of Canada (SOGC) annual meeting, where Natural Cycles sponsored a session on digital contraception. The company's standard figures are 98% effective with perfect use and 93% with typical use, which it says puts it in the same category as the pill. It is also forming a Canadian Medical Advisory Board of OB-GYNs, family physicians and reproductive-health specialists, with the first members to be named in early 2027.

The company frames this as a response to unmet need. It cites a Statistics Canada finding that among about 4.5 million sexually active Canadian women aged 15–49 trying to avoid pregnancy, one in five said they and their partner used no contraception the last time they had sex. "We're seeing substantial organic demand for Natural Cycles in Canada," said co-founder and CEO Dr. Elina Berglund Scherwitzl. Newly appointed CMO Rubina Singh, formerly CMO at Canadian fintech Wealthsimple, will lead awareness work globally. Natural Cycles reports more than six million registered users worldwide and six FDA clearances.

Sources

Update — 2026-10-08

Initial entry — story first created.